SPRB SPRUCE BIOSCIENCES, INC.
$52.21 +7.01%
Healthcare · Pharmaceutical Preparations
SPRUCE BIOSCIENCES, INC. (SPRB) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $144 million. Shares last traded at $52.21, 86.3% below their 52-week high. Over the past year the stock is up 13916.1%. Revenue declined 100.0% year over year.
Market Cap
$144M
Shares Out
2.8M
EPS (TTM)
$-101.50
P/E Ratio
—
P/S Ratio
—
P/B Ratio
4.15
Dividend / Share
—
Dividend Yield
—
52-Week High
$380.00
52-Week Low
$0.07
Volume
4,622
Avg Vol (3m)
2,205.175
Performance
1W
+6.83%
1M
+5.88%
3M
-12.98%
6M
-33.91%
YTD
-42.18%
1Y
+13916.11%
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
RSI (14)
51.09
SMA (50)
$55.22
SMA (200)
$71.39
Price vs SMA50
-5.44%
Price vs SMA200
-26.87%
ATR (14)
$3.37
Financials
Revenue
$0M
Net Income
$-39M
Gross Margin
—
Operating Margin
—
Net Margin
—
Return on Equity
-112.5%
Return on Assets
-69.4%
Current Ratio
4.67
Debt / Equity
0.59
Revenue Growth (YoY)
-100.0%
Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2026 | $-8.94 | 2026-05-13 |
| FY 2025 | $-50.83 | 2026-03-09 |
| Q3 2025 | $-41.25 | 2025-11-10 |
| Q2 2025 | $-27.36 | 2025-08-14 |
| Q1 2026 | $-23.95 | 2026-05-13 |
| FY 2025 | $-96.40 | 2026-03-09 |
Pharmaceutical Preparations peers
SPRB vs 14 industry peers (Pharmaceutical Preparations), by market cap.
1–14 of 14
| LLY | Lilly (Eli) | $1.04T | 50.16 | 15.88 | 31.7% | -1.17% |
| JNJ | Johnson & Johnson | $549.8B | 20.51 | 5.84 | 28.5% | -2.42% |
| ONC | Beone Medicines Ltd. | $390.6B | 1361.26 | 73.10 | 5.4% | +2.83% |
| ABBV | AbbVie | $382.5B | 90.51 | 6.25 | 6.9% | -2.16% |
| MRK | Merck | $281.6B | 15.43 | 4.33 | 28.1% | -1.30% |
| ABT | Abbott Laboratories | $154.3B | 23.65 | 3.48 | 14.7% | +0.09% |
| PFE | Pfizer | $143.7B | 18.50 | 2.30 | 12.4% | -2.89% |
| VRTX | Vertex Pharmaceuticals | $114.6B | 28.99 | 9.55 | 32.9% | -1.63% |
| BMY | Bristol Myers Squibb | $110.3B | 15.63 | 2.29 | 14.6% | -2.35% |
| REGN | Regeneron Pharmaceuticals | $63.4B | 14.08 | 4.42 | 31.4% | +0.38% |
| ALNY | Alnylam Pharmaceuticals | $36.9B | 117.57 | 9.93 | 8.4% | -1.66% |
| TEVA | Teva Pharmaceutical Industries Ltd | $36.6B | 25.98 | 2.12 | 8.2% | -3.33% |
| ZTS | Zoetis | $33.1B | 12.37 | 3.49 | 28.2% | +2.09% |
| RPRX | Royalty Pharma Plc | $23.1B | 30.02 | 9.73 | 32.4% | -1.30% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.